By adding paclitaxel to NSCLC control cells and MNX1-AS1-knockdown cells, we found that the viability of MNX1-AS1-knockdown NSCLC cells was lower than that in control cells. This evidence concerns the gene MNX1 and non-small cell lung carcinoma.